PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnruralpHomeCurrent issueInstructionsSubmit article
 
J Neurosci Rural Pract. 2011 Jan-Jun; 2(1): 56–61.
PMCID: PMC3122981
Effect of plant extracts on Alzheimer's disease: An insight into therapeutic avenues
M Obulesu and Dowlathabad Muralidhara Rao1
Capital College, Garden City Group of Institutions, Bangalore, India.
1Srikrishnadevaraya University, Anantapur, India.
Address for correspondence: M. Obulesu, Department of Biotechnology, Rayalaseema University, Kurnool, Andhra Pradesh
Alzheimer's disease (AD) is a devastative neurodegenerative disorder which needs adequate studies on effective treatment options. The extracts of plants and their effect on the amelioration of AD symptoms have been extensively studied. This paper summarizes the mechanisms like acetylcholinesterase (AChE) inhibition, modification of monoamines, antiamyloid aggregation effect, and antioxidant activity which are actively entailed in the process of amelioration of AD symptoms. These effects are induced by extracts of a few plants of different origin like Yizhi Jiannao, Moringa oleifera (Drumstick tree), Ginkgo Biloba (Ginkgo/Maidenhair tree), Cassia obtisufolia (Sicklepod), Desmodium gangeticum (Sal Leaved Desmodium), Melissa officinalis (Lemon Balm), and Salvia officinalis (Garden sage, common sage).
Keywords: Alzheimer's disease, antiamyloid aggregation, antioxidants, acetyl choline esterase inhibitors, plant extracts.
Alzheimer's association estimated that one in eight Americans above age of 65 years and half of the Americans above age of 85 years have been presently suffering from this devastative neurodegenerative disorder.[1] According to this estimation, the number of patients may reach 16 million by 2050[14] thus augmenting the economic cost of Alzheimer's disease (AD) health care system, which is 80-100 billion dollars presently.[1] Loss of cholinergic synapses in hippocampus and neocortex has been a consistent finding in AD, thus accentuating the need to employ a substantial strategy that regulates the AChE function to combat this defect.[1] Tacrine, donepezil, and rivastigmine are a few AChE inhibitors approved by U.S. Food and Drug Administration for the amelioration of AD symptoms.[1,5,6] Although advent of such inhibitors has been effective in function yet there has been augmenting need to quest for new drugs.[1] In the light of this fact, polyphenolic compounds from fruits and vegetables have been exploited because of their potential antioxidative properties.[1,712] There has been growing focus on traditional herbal medicines presently since the failure of existing treatments.[13] The first neurotransmitter found to be involved in AD is acetylcholine.[14] Therefore, there have been manifold studies to employ AChE inhibitors.
Plants provide wealth of bioactive compounds, which exert a substantial strategy for the treatment of neurological disorders such as Alzheimer's disease.[15] It has been recently shown that a Chinese herb, Yizhi Jiannao Granules is effective in improving AD symptoms, and it also aggravates such amelioration when combined with acupuncture.[16] Zeatin has been found to have a protective role against Aβ-induced neurotoxicity in PC12 cells and ameliorate scopolamine-induced amnesia in ICR mice.17
Growing lines of evidence suggests that among 73 native and naturalized plants collected from the central region of Argentina, organic fractions obtained from extracts of Achyrocline tomentosa (Marcela) (Asteraceae), Eupatorium viscidum (Common boneset) (Asteraceae), Ruprechtia apetala (manzano del campo) (Polygonaceae), Trichocline reptans (arnica) (Asteraceae), and Zanthoxylum coco (cochucho, coco) (Rutaceae) demonstrated substantial inhibition of AChE (higher than 80%)[Table 1].[15] Poncirus trifoliate (Trifoliate Orange) extract has been shown to inhibit AchE considerably.[1] Methoxsalen isolated from medicinal herbs Treculia obovoidea (Catterall) and Angelica archangelica (Garden Angelica), shows antimicrobial and anti-AchE activities in vitro.[1,18,19,20]
Table 1
Table 1
Neuroprotective mechanisms exerted by various plant extracts
Studies on the seeds of Cassia obtisufolia proved their neuroprotective role in mice via attenuation of secondary Ca2+ dysregulation and mitochondrial toxin 3-NP.[13] Moreover, they can improve memory impairment via AChE inhibition.[13,21] Flavonoids, a group of phenolic compounds which demonstrate antimutagenic, anticarcinogenic, and antiageing properties[22,23,24,25] may be responsible for neuroprotective role of Cassia obtusifolia extracts.[13] Dried ginger has been shown to induce Ca2+ antagonistic activity and butylcholinesterase inhibitory activity which are effective in AD treatment.[26]
Moringa oleifera (MO) which belongs to the family Moringaceae, is prevalent almost all over the Asian and African countries. Its fruit and leaves which show anti-inflammatory and hypotensive effect are consumed as food by the people.[2729] It has been found recently that Moringa oleifera leaf extract which is not toxic even at higher concentration levels, enhances memory via nootropics activity and provides substantial antioxidants like vitamin C and E to combat oxidative stress in AD.[27,3032] Wealth of studies substantiated that monoamines entailed in the memory loss are altered by Moringa oleifera leaf extracts [Table 1].[27,33] Several lines of evidence also suggest that colchicines-induced AD can be ameliorated by ethanolic extract of Moringa oleifera by modifying the brain monoamines (norepinephrine, dopamine, and serotonin) and electrical activity in a rat model.[27]
Ginkgo biloba being a potential store house of antioxidants offers ample of health benefits to AD patients like antiamyloid aggregation effect [Table 1].[3436] Extensive studies on Ginkgo biloba revealed that 240 mg of Ginkgo biloba per day can decrease the incidence of AD.[34] Although there are a few substantial studies on Ginkgo biloba to ameliorate AD symptoms and worldwide sales of it exceed $249 million annually in the United States,[34] yet there has been augmenting need to initiate more promising clinical trials in this direction.[34] It has been found that the Ginkgo biloba extracts ameliorate cognitive defects in a mouse model of AD (Tg2576).[37,38] Manifold clinical trials proved amelioration of AD symptoms[39,40] and the clinical evaluation of EGb 761 that is widely used for dementia in many countries and an extensively used dietary supplement in the United States for memory enhancement,[4144] is presently in progress.[45] Although in vivo mechanism for EGb 761 is elusive yet it has been found to ameliorate AD symptoms both in vivo (AD mice Tg 2576)[46] and in vitro.[36,37,4751] Upregulation of a small APP release, a nontoxic, nonamyloidogenic metabolite of APP, via a PKC-independent manner in hippocampi and cortices of EGb761-treated rats has been studied.[37,52]
Desmodium gangeticum generally known as Salparni, is prevalent in India and has significant medicinal use as a bitter tonic, febrifuge, digestive, anticatarrhal, antiemetic,[53,54] and anti-inflammatory conditions.[53,55] Moreover, it has been extensively used in ayurveda for the amelioration of neurological symptoms.[53] Its extracts employed in mice to evaluate the efficacy in amelioration of AD symptoms via nootropic activity and deterioration of AChE activity yielded considerable outcome.[53] It also possesses antioxidative property [Table 1].[53,56]
Rosmarinic acid isolated from Salvia officinalis, attenuates a number of events provoked by Aβ-like reactive oxygen species formation, lipid peroxidation, DNA fragmentation, caspase-3 activation, and tau protein hyperphosphorylation.[57,58] Despite a few pharmacological activities of sage attributed[59] to AD include antioxidant activity,[60] anti-inflammatory effects[61] and cholinesterase inhibition,[62] yet the mode of sage-protective action is unclear.[57] Rosmarinic acid has been known to initiate antioxidant, anti-inflammatory, antimutagen, antibacterial, and antiviral properties.[63] Rosmarinic acid effectively inhibits hall mark events of AD-like formation of fibrils from Aβ, destabilization preformed Aβ fibrils in vitro and tau hyperphosphorylation.[57,64]
Kihi-to, a traditional Japanese-Chinese traditional medicine, shows significant amelioration of Aβ(25–35)-induced impairments in memory acquisition, memory retention, and object recognition memory in mice. It also attenuates neuritic, synaptic, and myelin losses in the cerebral cortex, hippocampus and striatum. Kihi-to also effectively attenuates the calpain augmentation in the cerebral cortex and hippocampus.[65] Abundance of research revealed that among several traditional Chinese medicines, Ginseng Radix[66,67] Astragali Radix[68] and Polygalae Radix[69] demonstrated potential axonal extension activity against amyloid β (Aβ) (25–35)-induced axonal atrophy.[65]
Among the 90 traditional Korean tea plants, methanolic extracts of Pueraria thunbergiana (Kudzu) rich in Daidzein (4,7 dihydroxy isoflavone), are actively entailed in the amelioration of scopolamine induced amnesia in mice.[70] Abundance of research unraveled the neuroprotective effect of Gossypium Herbaceam extracts against ibotenic acid induced learning and memory impairment in rats.[71]
Melissa officinalis extract has been proven to ameliorate mild to moderate AD.[14] Among the European herbs M. officinalis and another herb in the labiatae family, S. officinalis, might present a natural treatment for AD by amelioration of cognition.[14,58,72] This herb actively amends mood and cognitive ability during acute administration in healthy young volunteers and has no side effects or symptoms of toxicity.[14,73,74,75] S. triloba (Greek Sage) and Teucrium polium (Cat Thyme) are also effective in amelioration of AD symptoms.[76]
Formulation of some Indian medicinal plants classified in Ayurveda, the classic Indian system of medicine, as Medhyarasayanas or drugs considerably ameliorates memory and intellect.[77,78] Studies on rats demonstrated that the oral administration of Trasina, a herbal formulation, once daily for 21 days can effectively ameliorate colchicine induced effects like reduced frontal, cortical and hippocampal acetylcholine (Ach) concentrations, choline acetyltransferase (ChAT) activity, and muscarinic cholinergic receptor (MCR) binding.[77] It has been reported recently that alcoholic extract of Bacopa monnieri (Water Hyssop) significantly improves escape latency time in Morris water maze test and ameliorates reduction of neurons and cholinergic neuron densities in Wistar rats which are employed as AD animal models.[79] Anwala churna (Emblica officinalis Gaertn.), an Ayurvedic preparation showed an exemplary improvement in memory and brain cholinesterase activity, thus ameliorating the scopolamine induced amnesia in young and aged mice.[80]
Curcuma longa (Turmeric) has been the source of Curcumin (diferuloylmethane), an orange–yellow component of turmeric or curry powder. This being a potential polyphenol natural product has been predominantly used in some medicinal preparation or used as a food-coloring agent. Wealth of studies in vitro and in vivo substantiated that curcumin has anticancer, antiviral, antiarthritic, anti-amyloid, antioxidant, and anti-inflammatory properties. The molecular underpinnings of these effects have been found to involve the regulation of diverse molecular targets, including transcription factors (such as nuclear factor-κB), growth factors (such as vascular endothelial cell growth factor), inflammatory cytokines (such as tumor necrosis factor, interleukin 1 and interleukin 6), protein kinases (such as mammalian target of rapamycin, mitogen-activated protein kinases, and Akt) and other enzymes (such as cyclooxygenase 2 and 5 lipoxygenase). Its ability to regulate multiple targets and its safety for human use, made curcumin an amenable therapeutic agent for the prevention and/or treatment of various malignant diseases, arthritis, allergies, AD, and other inflammatory illnesses.[81]
Recent studies on cultured astrocytes obtained from pregnant Sprague-Dawley (SD) rat and neonatal 0–2-day-old SD rats showed improved neuronal survival by curcumin treatment in NMDA toxicity through the activation of PI3K/MAPK signaling pathways.[82] Studies employing surface plasmon resonance experiments, unraveled that the liposomes exposing the curcumin derivative (maintaining the planarity) demonstrate considerable affinity for Aβ1-42 fibrils (1–5 nM), through the exhibition of multivalent interactions, thus opening an amenable therapeutic avenue unlike the nonplanar curcumin.[83]
Conclusion
There have been manifold studies to combat this dreadful neurodegenerative disorder for a few decades. Although a few drugs are available today for the management of AD and many plants and their extracts are extensively employed in animal studies and AD patients, yet no substantial drug or plant extract is able to reverse the AD symptoms adequately. The intervention of phytotherapy, which entails the use of herbal medicines may be a potential corner stone based on which treatment strategies can be streamlined.[14,8486] It is tangible that there has been augmenting need for such therapeutic intervention.
Footnotes
Source of Support: Nil
Conflict of Interest: None declared.
1. Kim JK, Bae H, Kim MJ, Choi SJ, Cho HY, Hwang HJ, et al. Inhibitory effect of poncirus trifoliate on acetyl cholinesterase and attenuating activity against trimethyltin induced learning and memory impairment. Biosci Biotechnol Biochem. 2009;73:1105–12. [PubMed]
2. Heo HJ, Kim MJ, Lee JM, Choi SJ, Cho HY, Hong BS, et al. Naringenin from Citrus junos has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia. Dement. Geriatr. Cogn Disord. 2004;17:151–7. [PubMed]
3. Prasad KN, Hovland AR, Cole WC, Prasad KC, Nahreini P, Edwards-Prasad J, et al. Multiple antioxidants in the prevention and treatment of Alzheimer disease: Analysis of biologic rationale. Clin Neuropharmacol. 2000;23:2–13. [PubMed]
4. Terry RD, Masliah E. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–80. [PubMed]
5. Candy JW, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci. 1983;59:277–89. [PubMed]
6. Loizzo MR, Tundis R, Menichini F, Menichini F. Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: An update. Curr Med Chem. 2008;12:1209–28. [PubMed]
7. Ak T, Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact. 2008;174:27–37. [PubMed]
8. Gulcin I. Antioxidant activity of caffeic acid (3,4-dihydroxycinnamic acid) Toxicology. 2006;217:213–20. [PubMed]
9. Burda S, Oleszek W. Antioxidant and antiradical activities of flavonoids. J Agric Food Chem. 2001;49:2774–9. [PubMed]
10. Cardenas M, Marder M, Blank VC, Roguin LP. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg Med Chem. 2006;14:2966–71. [PubMed]
11. Li N, Liu JH, Zhang J, Yu BY. Comparative evaluation of cytotoxicity and antioxidative activity of 20 flavonoids. J Agric Food Chem. 2008;56:3876–83. [PubMed]
12. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, et al. Bioactive compounds in foods: Their role in the prevention of cardiovascular disease and cancer. Am J Med. 2002;113:71S–88S. [PubMed]
13. Drever BD, Anderson WG, Riedel G, Kim DH, Ryu JH, Choi DY, et al. The seed extract of cassia obtusifolia offers neuroprotection to mouse hippocampal cultures. J Pharmacol Sci. 2008;107:380–92. [PubMed]
14. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry. 2003;74:863–6. [PMC free article] [PubMed]
15. Carpinella MC, Andrione DG, Ruiz G, Palacios SM. Screening for acetylcholinesterase inhibitory activity in plant extracts from Argentina. Phytother Res. 2009;24:259–63. [PubMed]
16. Peng XW, Dong KL. Clinical observation on acupuncture combined with Yizhi Jiannao granules for treatment of Alzheimer's disease. Zhongguo Zhen Jiu. 2009;29:269–71. [PubMed]
17. Choi SJ, Jeong CH, Choi SG, Chun JY, Kim YJ, Lee J, et al. Zeatin prevents amyloid beta-induced neurotoxicity and scopolamine-induced cognitive deficits. J Med Food. 2009;12:271–7. [PubMed]
18. Kuete V, Ngameni B, Simo CC, Tankeu RK, Ngadjui BT, Meyer JJ, et al. Antimicrobial activity of the crude extracts and compounds from Ficus chlamydocarpa and Ficus cordata (Moraceae) J Ethnopharmacol. 2008;120:17–24. [PubMed]
19. Sigurdsson S, Gudbjarnason S. Antimicrobial activity of the crude extracts and compounds from Ficus chlamydocarpa and Ficus cordata (Moraceae) Z Naturforsch C. 2007;62:689–93. [PubMed]
20. Yu J, Wang L, Walzem RL, Miller EG, Pike LM, Patil BS. Antioxidant activity of citrus limonoids, flavonoids, and coumarins. J Agric Food Chem. 2005;53:2009–14. [PubMed]
21. Kim DH, Yoon BH, Kim YM, Lee S, Shin BY, Jung JW, et al. The seed extract of cassia obtusifolia ameliorates learning and memory impairments induced by scopolamine or transient cerebral hypoperfusion in mice. J Pharmacol Sci. 2007;105:82–93. [PubMed]
22. Bahorun T, Gressier B, Trotin F, Brunet C, Dine T, Luyckx M, et al. Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations. Arzneimittelforschung. 1996;46:1086–9. [PubMed]
23. Bahorun T, Aumjaud E, Ramphul H, Rycha M, Luximon-Ramma A, Trotin F, et al. Phenolic constituents and antioxidant capacities of crataegus monogyna (hawthorn) callus extracts. Nahrung. 2003;47:191–8. [PubMed]
24. Lien EJ, Ren S, Bui HH, Wang R. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic Biol Med. 1999;26:285–94. [PubMed]
25. Luximon-Ramma A, Bahorun T, Soobrattee MA, Aruoma OI. Antioxidant activities of phenolic, proanthocyanidin, and flavonoid components in extracts of cassia fistula. J Agric Food Chem. 2002;50:5042–7. [PubMed]
26. Ghayur MN, Gilani AH, Ahmed T, Khalid A, Nawaz SA, Agbedahunsi JM, et al. Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia. J Pharm Pharmacol. 2008;60:1375–83. [PubMed]
27. Ganguly R, Guha D. Alteration of brain monoamines and EEG wave pattern in rat model of Alzheimer's disease and protection by Moringa oleifera. Indian J Med Res. 2008;128:744–51. [PubMed]
28. Faizi S, Siddiqui BS, Saleem R, Siddiqui S, Aftab K, Gilani AH. Fully acetylated carbamates and hypotensive thiocarbamate glycosides from Moringa oleifera. Phytochemistry. 1995;38:957–63. [PubMed]
29. Caceres A, Saravia A, Rizzo S, Zabala L, Leon ED, Nave F. Pharmacological properties of Moringa oleifera.2: Screening for antispasmodic, anti-inflammatoryand diuretic activity. J Ethnopharmacol. 1992;36:233–7. [PubMed]
30. Majumdar K, Gupta M, Chakrobarty S, Pal DK. Evaluation of hematological and hepatorenal functions of methanolic extract of Moringa oleifera Lam.root treated mice. Indian J Exp Biol. 1999;37:612–4. [PubMed]
31. Mohan M, Kaul N, Punekar A, Girnar R, Junnare P, Patil L. Nootropic activity of Moringa oleifera leaves. J Nat Remedies. 2005;5:59–62.
32. Ganguly R, Hazra R, Ray K, Guha D. Effect of Moringa oleifera in experimental model of Alzheimer's disease: Role of antioxidants. Ann Neurosci. 2005;12:36–9.
33. Ganguly R, Guha D. Protective role of an Indian herb, Moringa oleifera in memory impairment by high altitude hypoxic exposure: Possible role of monoamines. Biogenic Amines. 2006;20:121–33.
34. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia a randomized controlled trial. JAMA. 2008;300:2253–62. [PMC free article] [PubMed]
35. Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761) J Mol Cell Cardiol. 1997;29:733–42. [PubMed]
36. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002;99:12197–202. [PubMed]
37. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J. 2007;21:2400–8. [PubMed]
38. Augustin S, Rimbach G, Augustin K, Schliebs R, Wolffram S, Cermak R. Effect of a short- and long-term treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease. Arch Biochem Biophys. 2009;481:177–82. [PubMed]
39. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25–58. [PubMed]
40. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol. 2004;64:465–72. [PubMed]
41. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia: North American EGb Study Group. J Am Med Assoc. 1997;278:1327–32. [PubMed]
42. Oken BS, Storzzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55:1409–15. [PubMed]
43. Mix JA, David Crews W., Jr A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761(R) in a sample of cognitively intact older adults: Neuropsychological findings. Hum Psychopharmacol. 2002;17:267–77. [PubMed]
44. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: A comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled doubleblind study. Eur J Neurol. 2006;13:981–5. [PubMed]
45. DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, et al. The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials. 2006;27:238–53. [PubMed]
46. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol. 2003;184:510–20. [PubMed]
47. Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: Involvement of its flavonoid constituents and protein kinase C. J Neurochem. 2000;74:2268–77. [PubMed]
48. Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 2001;889:181–90. [PubMed]
49. Gohil K, Packer L. Bioflavonoid-rich botanical extracts show antioxidant and gene regulatory activity. Ann N Y Acad Sci. 2002;957:70–7. [PubMed]
50. Smith JV, Burdick AJ, Golik P, Khan I, Wallace D, Luo Y. Anti-apoptotic properties of Ginkgo biloba extract EGb 761 in differentiated PC12 cells. Cell Mol Biol (Noisy-le-grand) 2002;48:699–707. [PubMed]
51. Spencer JP, Rice-Evans C, Williams RJ. Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J Biol Chem. 2003;278:34783–93. [PubMed]
52. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis. 2004;16:454–60. [PubMed]
53. Joshi H, Parle M. Antiamnestic effects of Demodium gangeticum in mice. Yakugaku Zasshi. 2006;126:795–804. [PubMed]
54. Chopra RN, Nayar SL, Chopra IC. New Delhi: Council of Scientifi c and Industrial Research; 1956. Glossary of Indian Medicinal Plants.
55. Purushothaman KK, Chandrasekharan S, Balakrishna K, Connolly JD. Gangetinin and desmodin, two minor pterocarpanoids of Desmodium gangeticum. Phytochemistry. 1975;14:1129–30.
56. Govindarajan R, Rastogi S, Vijayakumar M, Shirwaikar A, Rawat AK, Mehrotra S, et al. Studies on the antioxidant activities of Desmodium gangeticum. Biol Pharm Bull. 2003;26:1424–7. [PubMed]
57. Iuvone T, De Filippis D, Esposito G, D'Amico A, Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 Cells from amyloid: Peptide-induced neurotoxicity. J Pharmacol Exp Ther. 2006;317:1143–9. [PubMed]
58. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer's disease: From ethnobotany to phytotherapy.J Pharm. Pharmacol. 1999;51:527–34. [PubMed]
59. Howes MJ, Perry NS, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res. 2003;17:1–18. [PubMed]
60. Hohmann J, Zupko I, Redei D, Csanyi M, Falkay G, Mathe I, et al. Protective effects of the aerial parts of Salvia officinalis, Melissa officinalis and Lavandula angustifolia and their constituents against enzyme-dependent and enzyme-independent lipid peroxidation. Planta Med. 1999;65:576–8. [PubMed]
61. Baricevic D, Sosa S, Della Loggia R, Tubaro A, Simonovska B, Krasna A, et al. Topical anti-inflammatory activity of Salvia officinalis L.leaves: The relevance of ursolic acid. J Ethnopharmacol. 2001;75:125–32. [PubMed]
62. Perry N, Court G, Bidet N, Court J, Perry E. European herbs with cholinergic activities: potential in dementia therapy. Int J Geriatr Psychiatry. 1996;11:1063–9.
63. Petersen M, Simmonds MS. Rosmarinic acid. Phytochemistry. 2003;62:121–5. [PubMed]
64. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent antiamyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res. 2004;15:742–50. [PubMed]
65. Tohda C, Naito R, Joyashiki E. Kihi-to, a herbal traditional medicine, improves A beta (25-35)-induced memory impairment and losses of neuritis and synapses. BMC Compl Alternat Med. 2008;8:49. [PMC free article] [PubMed]
66. Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K. Axonal and dendritic extension by protopanaxadiol-type saponins from ginseng drugs in SK-N-SH cells. Jpn J Pharmacol. 2002;90:254–62. [PubMed]
67. Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K. Aβ(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol- type saponins. Neuropsychopharmacology. 2004;29:860–8. [PubMed]
68. Tohda C, Tamura T, Matsuyama S, Komatsu K. Promotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicus. Br J Pharmacol. 2006;149:532–41. [PubMed]
69. Naito R, Tohda C. Characterization of anti-neurodegenerative effects of Polygala tenuifolia in Aβ(25-35)-treated cortical neurons. Biol Pharm Bull. 2006;29:1892–6. [PubMed]
70. Heo HJ, Suh YM, Kim MJ, Choi SJ, Mun NS, Kim HK, et al. Daidzein activates choline acetyltransferase from mc-IXC cells and improves drug-induced amnesia. Biosci Biotechnol Biochem. 2006;70:107–11. [PubMed]
71. Ji C, Li Q, Aisa H, Yang N, Dong YL, Liu YY, et al. Gossypium herbaceam extracts attenuate ibotenic acid-induced excitotoxicity in rat hippocampus. J Alzheimers Dis. 2009;16:331–9. [PubMed]
72. Perry EK, Pikering AT, Wang WW, Houghton P, Perry NS. Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. J Altern Complement Med. 1998;4:419–28. [PubMed]
73. Schhultz V, Hansel R, Tyler V. New York: Springer-Verlag; 1998. Rational phytotherapy: A physician's guide to herbal medicine.
74. Wake G, Court J, Pikering A, Lewis R, Wilkins R, Perry E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol. 2000;69:105–14. [PubMed]
75. Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm) Pharmacol Biochem Behav. 2002;72:953–64. [PubMed]
76. Orhan I, Aslan M. Appraisal of scopolamine-induced antiamnesic effect in mice and in vitro antiacetylcholinesterase and antioxidant activities of some traditionally used Lamiaceae plants. J Ethnopharmacol. 2009;122:327–32. [PubMed]
77. Bhattacharya SK, Kumar A. Effect of Trasina, an ayurvedic herbal formulation, on experimental models of Alzheimer's disease and central cholinergic markers in rats. J Altern Complement Med. 1997;3:327–36. [PubMed]
78. Kumar V. Potential medicinal plants for CNS disorders: An overview. Phytother Res. 2006;20:1023–35. [PubMed]
79. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol. 2010;127:26–31. [PubMed]
80. Vasudevan M, Parle M. Memory enhancing activity of Anwala churna (Emblica officinalis Gaertn.): An Ayurvedic preparation. Physiol Behav. 2007;91:46–54. [PubMed]
81. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets. 2011;12:332–47. [PMC free article] [PubMed]
82. Lin MS, Hung KS, Chiu WT, Sun YY, Tsai SH, Lin JW, et al. Curcumin enhances neuronal survival in N-methyl-D-aspartic acid toxicity by inducing RANTES expression in astrocytes via PI-3K and MAPK signaling pathways. Prog Neuropsychopharmacol Biol Psychiatry. 2011 [PubMed]
83. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials. 2011;32:1635–45. [PubMed]
84. Akhondzadeh S, Noroozian M. Alzheimer's disease: Pathophysiology and pharmacotherapy. I Drugs. 2002;4:1167–72. [PubMed]
85. Bullock R. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry. 2002;180:135–9. [PubMed]
86. Bullock R. Drug treatment in dementia. Curr Opin Psychiatry. 2001;14:349–53.
Articles from Journal of Neurosciences in Rural Practice are provided here courtesy of
Medknow Publications